Clinical Trial Update: Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for intensive, non-cross reactive therapy in castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-02-07